{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:41:04Z","timestamp":1785426064892,"version":"3.56.0"},"reference-count":30,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["U10 CA180821"],"award-info":[{"award-number":["U10 CA180821"]}]},{"name":"NIH","award":["UG1 CA189823"],"award-info":[{"award-number":["UG1 CA189823"]}]},{"name":"NIH","award":["U10 CA180882"],"award-info":[{"award-number":["U10 CA180882"]}]},{"award":["U10 CA180821"],"award-info":[{"award-number":["U10 CA180821"]}],"id":[{"id":"https:\/\/ror.org\/044zkrt47","id-type":"ROR","asserted-by":"publisher"}]},{"award":["UG1 CA189823"],"award-info":[{"award-number":["UG1 CA189823"]}],"id":[{"id":"https:\/\/ror.org\/044zkrt47","id-type":"ROR","asserted-by":"publisher"}]},{"award":["U10 CA180882"],"award-info":[{"award-number":["U10 CA180882"]}],"id":[{"id":"https:\/\/ror.org\/044zkrt47","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives. Decades of research have failed to uncover effective approaches to prevent chemotherapy-induced peripheral neuropathy (CIPN), a common side effect of neurotoxic chemotherapy. Increased interest in placebo response as a potentially under-recognized confounder in CIPN trials was recently sparked by the results of a multisite NCI-funded phase II-III CIPN prevention study of duloxetine, a promising serotonin\u2013norepinephrine reuptake inhibitor that enhances pain-inhibitory mechanisms within the central nervous system. Study findings revealed high and nearly equivalent response rates in three randomized treatment groups\u2014little to no CIPN was reported by 65.2%, 66.0%, and 68.0% of study participants who received duloxetine 30 mg, 60 mg, or placebo treatment, respectively. Methods. We performed a meta-analysis of placebo response rates from seven randomized, double-blinded, placebo-controlled trials conducted over the past 20 years and comprising 191 placebo participants that were specifically testing interventions for oxaliplatin- and paclitaxel-induced peripheral neuropathy and that serially collected patient responses on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Neuropathy questionnaire. Additionally, we sought to identify trial- and patient-specific factors that predicted higher placebo response rates from a participant-level pooled analysis. Results. The placebo response rate was 10.0% [95% CI: 5.8%, 16.6%] when response was defined more conservatively as patients reporting no neuropathy at all. When the placebo response was defined more broadly based on patients reporting no or a little neuropathy, the placebo response rate was higher (39.6% [95% CI: 27.4%, 53.2%]). Male participants, receipt of oxaliplatin, and a 2:1 randomization ratio favoring the intervention arm were individually associated with a higher placebo response. Conclusions. High placebo response rates can threaten scientific progress toward identifying effective treatments for cancer treatment-associated side effects, like CIPN. Careful attention to study design factors, participant eligibility, and patient and research staff expectations may help to minimize placebo response rates in future CIPN intervention studies.<\/jats:p>","DOI":"10.3390\/cancers18101514","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T20:14:16Z","timestamp":1778530456000},"page":"1514","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0529-5146","authenticated-orcid":false,"given":"David","family":"Zahrieh","sequence":"first","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-714X","authenticated-orcid":false,"given":"Daniel","family":"Satele","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4323-280X","authenticated-orcid":false,"given":"Hiboombe","family":"Haamankuli","sequence":"additional","affiliation":[{"name":"Department of Acute, Chronic, and Continuing Care, University of Alabama at Birmingham School of Nursing, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Shelley","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2234-7430","authenticated-orcid":false,"given":"Jennifer G.","family":"Le-Rademacher","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1301-4319","authenticated-orcid":false,"given":"Minji","family":"Lee","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heshan","family":"Liu","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Diaz-Cobo","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN 55905, USA"},{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-5397","authenticated-orcid":false,"given":"Shu-En","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5897-8107","authenticated-orcid":false,"given":"Selina","family":"Chow","sequence":"additional","affiliation":[{"name":"Alliance Protocol Operations Office, University of Chicago, Chicago, IL 60606, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, CT 06520, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-332X","authenticated-orcid":false,"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-6636","authenticated-orcid":false,"given":"Ellen M. Lavoie","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Acute, Chronic, and Continuing Care, University of Alabama at Birmingham School of Nursing, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: A current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","article-title":"Chemotherapy-induced peripheral neuropathy: Where are we now?","volume":"160","author":"Colvin","year":"2019","journal-title":"Pain"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Li, Y., Lustberg, M.B., and Hu, S. (2021). Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers, 13.","DOI":"10.3390\/cancers13040766"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"217433","DOI":"10.1016\/j.canlet.2024.217433","article-title":"An emerging aspect of cancer neuroscience: A literature review on chemotherapy-induced peripheral neuropathy","volume":"611","author":"Tao","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0000000000006083","article-title":"Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations","volume":"91","author":"Gewandter","year":"2018","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/npp.2013.342","article-title":"Innovative drugs to treat depression: Did animal models fail to be predictive or did clinical trials fail to detect effects?","volume":"39","author":"Belzung","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nrn3976","article-title":"The neuroscience of placebo effects: Connecting context, learning and health","volume":"16","author":"Wager","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_10","first-page":"107","article-title":"Placebo response in clinical trials with schizophrenia patients","volume":"24","author":"Kinon","year":"2011","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","article-title":"Placebo response in antipsychotic clinical trials: A meta-analysis","volume":"71","author":"Rutherford","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13063-021-05454-8","article-title":"Placebo response and effect in randomized clinical trials: Meta-research with focus on contextual effects","volume":"22","author":"Juhl","year":"2021","journal-title":"Trials"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1111\/bcp.15345","article-title":"How do they add up? The interaction between the placebo and treatment effect: A systematic review","volume":"88","author":"Boussageon","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e84691","DOI":"10.7554\/eLife.84691","article-title":"Presenting a sham treatment as personalised increases the placebo effect in a randomised controlled trial","volume":"12","author":"Sandra","year":"2023","journal-title":"eLife"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/j.pain.0000000000003000","article-title":"Placebo and nocebo responses in painful diabetic neuropathy: Systematic review and meta-analysis","volume":"165","author":"Frisaldi","year":"2024","journal-title":"Pain"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2500107","DOI":"10.1200\/OA-25-00107","article-title":"Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study","volume":"3","author":"Lee","year":"2026","journal-title":"JCO Oncol. Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jpainsymman.2019.06.018","article-title":"Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial","volume":"58","author":"Wang","year":"2019","journal-title":"J. Pain Symptom Manag."},{"key":"ref_18","first-page":"1071","article-title":"MC11C4: A pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy","volume":"24","author":"Zimmerman","year":"2016","journal-title":"Support Care Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","article-title":"Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance)","volume":"32","author":"Loprinzi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_20","first-page":"3407","article-title":"A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I","volume":"25","author":"Pachman","year":"2017","journal-title":"Support Care Cancer"},{"key":"ref_21","first-page":"547","article-title":"Can pregabalin prevent paclitaxel-associated neuropathy?\u2014An ACCRU pilot trial","volume":"24","author":"Shinde","year":"2016","journal-title":"Support Care Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/cncr.28654","article-title":"North Central Cancer Treatment Group\/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel\/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study","volume":"120","author":"Leal","year":"2014","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20","volume":"41","author":"Postma","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1188\/17.ONF.580-588","article-title":"The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure","volume":"44","author":"Haupt","year":"2017","journal-title":"Oncol. Nurses Forum"},{"key":"ref_25","first-page":"2599","article-title":"Rasch model-based testing of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data","volume":"27","author":"Smith","year":"2019","journal-title":"Support Care Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1073274818756608","DOI":"10.1177\/1073274818756608","article-title":"In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials","volume":"25","author":"Smith","year":"2018","journal-title":"Cancer Control"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Khan, S. (2020). Meta-analysis on One Proportion. Meta-Analysis: Methods for Health and Experimental Studies, Springer.","DOI":"10.1007\/978-981-15-5032-4"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jclinepi.2014.05.015","article-title":"Rationale for unequal randomization in clinical trials is rarely reported: A systematic review","volume":"67","author":"Caille","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cho, Y., Scott, M.R., Wilson, C.M., Daniel, M., Odii, C.O., Wang, H.L., Carlee, J., Kreider, J., and Smith, E.M.L. (2025). Nurse Liaison Support to Safeguard the Scientific Rigor of Multisite Clinical Trials: Qualitative Findings From Communications Between Clinical Research Professionals. Cancer Nurs.","DOI":"10.1097\/NCC.0000000000001528"},{"key":"ref_30","first-page":"29","article-title":"Meta-analysis in medical research","volume":"14","author":"Haidich","year":"2010","journal-title":"Hippokratia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1514\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:44:31Z","timestamp":1778561071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101514"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101514","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}